[Breaking] EuBiologics Files Domestic Phase 1 IND for Alzheimer's Vaccine 'PADIVAX' with MFDS
EuBiologics announced on the 18th that it has submitted an Investigational New Drug (IND) application for a Phase 1 clinical trial of its Alzheimer's disease vaccine 'PADIVAX' to Korea's Ministry of Food and Drug Safety (MFDS). The disclosure date marks the day the company confirmed that its clinic
![[Breaking] EuBiologics Files Domestic Phase 1 IND for Alzheimer's Vaccine 'PADIVAX' with MFDS](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F06%2F581911%2Fa630da1c47d6049c%2Foriginal.webp&w=1920&q=75)
EuBiologics announced on the 18th that it has submitted an Investigational New Drug (IND) application for a Phase 1 clinical trial of its Alzheimer's disease vaccine 'PADIVAX' to Korea's Ministry of Food and Drug Safety (MFDS).
The disclosure date marks the day the company confirmed that its clinical trial plan had been submitted to the MFDS.
Study Targets 24 Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease
This Phase 1 clinical trial aims to evaluate the safety, tolerability, and immunogenicity of PADIVAX in patients with mild cognitive impairment (MCI) due to Alzheimer's disease and mild Alzheimer's disease. It will be conducted at a single domestic clinical trial institution as a single-center, double-blind, randomized, placebo-controlled study.
The target number of subjects is 24, and the trial period is 60 months from the date of Institutional Review Board (IRB) approval. Subjects will be enrolled in order of low-dose, mid-dose, and high-dose groups, and within each dose group, they will be randomly assigned to either the treatment group or the placebo control group. Subjects who pass the final eligibility assessment will receive the investigational drug a total of five times at four-week intervals, and safety evaluations will be conducted up to 52 weeks after the final vaccination.
Exploratory Phase 1 Involving 'First Administration in Humans'
According to the disclosure, PADIVAX is a drug being administered to humans for the first time. This clinical trial is an exploratory study and does not test statistical hypotheses, so the number of subjects was not statistically determined. It does not qualify as a clinical trial that verifies or demonstrates efficacy differences between the treatment and control groups with statistical significance.
Approval Probability Around 10%... Commercialization Plans May Be Changed or Abandoned
EuBiologics stated that it will immediately make a related disclosure upon approval of the clinical trial plan.
The company also noted in its investor cautionary statements that the statistical probability of a clinical trial drug ultimately receiving drug approval is known to be around 10%. Results during the clinical trial and product approval process may fall short of expectations, meaning there is a possibility that commercialization plans could be changed or abandoned.
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



